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Abstract: Traumatic brain injury (TBI) is a common occurrence in the United States, with
an estimated incidence exceeding 1 million injuries per year. Cognitive, emotional, behavioral,
and physical impairments are common sequelae of TBI and may, in a significant minority of
patients, persist well into the late period following injury. The etiology of these symptoms in
individuals with mild TBI is controversial, with hypotheses of postconcussive symptom
formation variously ascribing greater or lesser weight to neural damage, pre- and/or post-
injury psychological or psychiatric factors, somatization, malingering, or some combination
of these. Some of these hypotheses reflect biases common to medicolegal or compensation-
related contexts, whereas others are derived from recent neuroimaging and electrophysiology
studies. Studies of the latter sort suggest that many of the typical postconcussive symptoms
are associated with neurobiological dysfunction in one or more areas of the central nervous
system. Whether these symptoms constitute a postconcussive syndrome per se is debatable.
Instead, it may be more accurate to describe them as commonly co-occurring symptoms rather
than as a syndromal sequela of TBI. The present review addresses these issues including the
epidemiology and course of recovery from mild TBI and the validity of the postconcussive
syndrome. Suggestions regarding the assessment and treatment of individuals with post-
concussive symptoms are offered.
Keywords: traumatic brain injury, postconcussive syndrome, neuroimaging, electro-
encephalography, diagnosis, treatment
Introduction
Each year in the United States, 235 000 people experience a traumatic brain injury
(TBI) that requires hospitalization, and as many as 1.1 million additional individuals
experience a TBI for which they are evaluated and released from an emergency
department (National Center for Injury Prevention and Control 2004). TBI is
bimodally distributed by age, with the highest rates of injury occurring in those aged
15–24 years and those older than 65 years (Kraus and Nourjah 1988). The majority
of TBI results from motor vehicle accidents, assaults, and falls (Kraus and Nourjah
1988), the first of these two causes being more frequent in younger and urban dwelling
persons and the third being more common among the elderly. Among persons that
experience a TBI requiring hospitalization, 50 000 die as a result of their injuries,
and an additional 80 000 develop partial or total permanent disabilities (National
Center for Injury Prevention and Control 2004). Approximately 5.3 million Americans
are presently living with chronic disabilities due to TBI, and the annual cost of TBI
in the United States exceeds $48 billion (Kraus and Sorenson 1994; National Center
for Injury Prevention and Control 2004).
Although many physicians are familiar with severe TBI and its management,
mild TBI comprises 70%–80% of all such injuries (Kraus and Nourjah 1988; Jennett
1996, 1998). The deficits produced by mild TBI are frequently more subtle, less
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often recognized, and more contentiously debated than are
those resulting from severe TBI (MacKenzie et al 1989;
Williams et al 1990; Katz and DeLuca 1992; Dikmen et al
2001). Given the large number of persons that experience
mild TBI each year, it is indeed fortunate that the majority
of these individuals recover fully within the first year
following TBI. However, a nontrivial minority of persons
with mild TBI, with estimates ranging between 1% and 20%
(Katz and DeLuca 1992; Dikmen et al 2001), will develop
persistent cognitive, emotional, behavioral, and physical
impairments that extend well into the late (> 1 year) period
following TBI.
Typical acute and/or chronic postconcussive symptoms
include physical problems such as headache, dizziness, and
visual disturbances; cognitive impairments such as attention,
memory, and executive dysfunction; and emotional or
behavioral problems such as irritability, anxiety, depression,
affective lability, apathy, and/or impulsivity. The develop-
ment of these symptoms is predicated on a complex set of
factors including neural injury produced by mild TBI,
expectational sets on the part of patients and clinicians, pre-
existing and/or comorbid post-traumatic psychiatric
disorders, and occasionally on conscious and/or unconscious
efforts to obtain primary and secondary gains (MacMillan
et al 2002; Wood 2004).
The cognitive, emotional, behavioral, and physical
impairments experienced by mild TBI survivors produce
substantial disability and costs (Levin, Mattis, et al 1987;
Kraus and Nourjah 1988; Montgomery et al 1991; Katz and
DeLuca 1992). Clinicians working with this population
should be familiar with recent advances in the basic and
clinical neuroscience of mild TBI in order to understand
accurately the symptoms with which their patients present
and also the treatments available for these symptoms.
In the service of this goal, the present article reviews the
clinical features of mild TBI, recent neuroscience findings
relevant to understanding this condition, and the validity of
the postconcussive syndrome. This review was predicated
on initial searches of the medical literature in PubMed and
MEDLINE using the terms “traumatic brain injury”, “brain
injury”, “closed head injury”, “craniocerebral trauma”, and
“concussion”. These searches were subsequently limited to
studies of humans and were anchored to the topic areas into
which this review is organized (ie, definition of mild TBI,
neurobiology, neuroimaging, electrophysiology, post-
concussive syndrome, evaluation, and treatment, with the
last of these categories including cognitive impairment,
emotional disturbances, and somatic symptoms). Where
information in the peer-reviewed literature was lacking
and/or where useful summaries of that literature sufficed
for the purpose of this review, information published in
major textbooks in the field was included. Data from these
reviews were synthesized to formulate a neuropsychiatric
approach to the issue of mild TBI, and to develop the
suggestions offered herein regarding the assessment and
treatment of individuals with postconcussive symptoms
following mild TBI.
Mild traumatic brain injury
Defining mild TBI
Traumatic brain injury is best defined as the result of the
application of either external physical force or rapid
acceleration/deceleration forces (eg, mechanical trauma, not
anoxia/hypoxia, tumor, stroke) that disrupts brain function
as manifested by immediately apparent impairments in
cognitive and/or physical function. It is important to note
that it is the application of such forces to the brain, rather
than to the head per se, that produces a TBI. In other words,
not all head injuries produce brain injuries, and some brain
injuries (particularly those resulting from acceleration/
deceleration forces) may occur without apparent head injury.
The Glasgow Coma Scale (GCS) (Teasdale and Jennett
1974) is the most widely known system for injury severity
classification in the acute injury period, and is useful when
performed properly in that context. The American Congress
of Rehabilitation Medicine (ACRM) (1993) definition of
mild traumatic brain injury may be of greater use to
clinicians attempting to determine after-the-fact whether an
event experienced by an individual is characterized fairly
as a mild TBI, particularly when GCS scores are unavailable
or invalid. This definition states that any one of the following
symptoms following external application of force to the
brain reflects an injury of severity sufficient to merit
classification as a mild TBI: any period of loss of
consciousness, any loss of memory for events immediately
before (retrograde amnesia) or after (anterograde amnesia)
the accident (collectively referred to as the period of post-
traumatic amnesia, or PTA), any alteration in mental state
at the time of the accident (eg, feeling dazed, disoriented,
or confused), or focal neurologic deficit(s) that may or may
not be transient. The ACRM definition of mild TBI includes
only those injuries in which loss of consciousness is 30
minutes or less, the GCS score at 30 minutes after injury is
13–15, and the duration of PTA is no longer than 24 hours.
Injuries exceeding these criteria are considered to be ofNeuropsychiatric Disease and Treatment 2005:1(4) 313
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more than mild severity. Although these criteria are not
without criticism (Ruff and Jurica 1999; Arciniegas and
Silver 2001), they are at present the most widely accepted
definition of mild TBI. In the absence of another universally
accepted minimum criteria set for this condition, the authors
recommend using these criteria to determine whether an
event experienced by a patient is characterized fairly as a
TBI.
Neurobiology of TBI
The biomechanical and cytotoxic consequences of mild TBI
may be substantial despite an ostensibly “mild” mechanism
of injury. Experimental injury models demonstrate that mild
brain injuries are capable of producing diffuse axonal injury,
both as a function of biomechanical forces and a host of
injury-mediated cytotoxic processes (ie, calcium and
magnesium regulation, free radical formation, neuro-
transmitter excitotoxicity, inflammatory responses,
disruption of vascular homeostasis) (Povlishock et al 1979,
1983; Povlishock 1992; Povlishock and Christman 1995).
TBI in humans appears similarly capable of producing
structural neuronal damage and/or diffuse neuronal
dysfunction (Christman et al 1994; Maxwell et al 1997;
Povlishock 1992, 2000; Povlishock and Jenkins 1995), and
are central – if perhaps transient – neuropathological features
of mild TBI in humans (Povlishock 1992; Povlishock and
Jenkins 1995). Alterations of neurotransmitter production
and/or delivery occur acutely and chronically following TBI
and some of these are related to acute and chronic cognitive
impairments following TBI (Povlishock 1992; Obrenovitch
and Urenjak 1997; Arciniegas 2003). Additionally,
neurogenetic factors may influence the extent of neural
injury produced by mild TBI. Recent studies suggest that
carrier status for the apolipoprotein epsilon-4 (ApoE-4)
allele may increase risk for poor outcome following TBI,
particularly among persons with more severe TBI or
repetitive mild TBI (Jordan et al 1997; Friedman et al 1999;
Lichtman et al 2000; Crawford et al 2002; Chiang et al 2003;
Nathoo et al 2003). Although the role of the ApoE-4 allele
in outcome following mild TBI is less clear (Liberman et al
2002; Chamelian et al 2004), our laboratory observed an
increased frequency of the ApoE-4 among persons with
persistent cognitive and electrophysiologic abnormalities
following mild TBI (Arciniegas et al 2003). We suggest that
while the presence of this allele may not influence outcome
in unselected groups of persons with mild TBI, it may be
overrepresented among persons who fail to make full
recoveries following mild TBI. Whether or to what extent
other genetic factors influence outcome following mild TBI
is the subject of active investigation.
Although many clinicians believe that mild TBI produces
no significant findings on conventional clinical neuro-
imaging (ie, CT or MRI scanning), this belief is not
supported by the literature (Williams et al 1990). In fact,
three recent large studies (Borczuk 1995; Miller et al 1997;
Haydel et al 2000) representing data from approximately
4000 persons with mild TBI (GCS = 15) demonstrate early
abnormalities on computed tomographic (CT) scanning in
5%–10% of these individuals. Studies evaluating CT
abnormalities among persons with GCS scores of 13 or 14
suggest a rate of 20%–35% (Harad and Kerstein 1992;
Shackford et al 1992; Stein and Ross 1992; Schynoll et al
1993). Importantly, neuroimaging abnormalities among
persons with mild TBI are associated with post-traumatic
cognitive sequelae comparable to those experienced by
persons with GCS-defined moderate TBI; accordingly,
persons with neuroimaging abnormalities in the context of
GCS-defined mild TBI are sometimes regarded as having
“complicated mild TBI” (Williams et al 1990; van der Naalt
et al 1999).
Studies using data acquisition and interpretation methods
more sensitive than those afforded by conventional clinical
neuroimaging consistently demonstrate significant post-
traumatic cerebral structural abnormalities, including
cortical and subcortical atrophy, ventricular dilation, and
white matter injury (Bigler et al 1992; Wood and Bigler
1995; Anderson et al 1996; Arciniegas et al 2001; Bigler
2001, 2003). While these studies vary in their methodology,
they all suggest that TBI, including mild TBI, is associated
with measurable reductions in the volumes of several
cerebral structures needed to maintain normal cognition and
behavior. Functional MRI (fMRI) studies demonstrate that
mild TBI produces abnormal allocation of memory
processing resources in the acute post-injury period even
among persons whose objective neuropsychological
performance appears relatively normal (McAllister et al
1999, 2001). Such abnormalities may underlie the subjective
experience of difficulty with memory even where
neuropsychological performance is within the normal range
(McAllister et al 1999). Studies using proton (Garnett,
Blamire, Corkill, et al 2000; Garnett, Blamire, Rajagopalan,
et al 2000) or phosphorus (Garnett et al 2001) magnetic
resonance spectroscopy (MRS) demonstrate cerebral white
matter abnormalities and metabolic abnormalities,
respectively, that are not otherwise apparent on conventionalNeuropsychiatric Disease and Treatment 2005:1(4) 314
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clinical neuroimaging. These imaging modalities reflect
more accurately the size or extent of damaged tissue than
either conventional CT or MRI, and abnormalities on MRS
are related to neuropsychological impairments in the late
period following TBI (Brooks et al 2000). Single photon
computed tomography (SPECT) studies (Choksey et al
1991; Roper et al 1991; Jacobs et al 1994; Mitchener et al
1997) and positron emission tomography (PET) studies
(Humayun et al 1989; Ruff et al 1994; Gross et al 1996)
also suggest that TBI may produce disturbances in brain
function even where such injuries do not produce structural
abnormalities visible on conventional neuroimaging (CT or
MRI). Although these studies include persons with a range
of TBI severity, they suggest that these neuroimaging
techniques may afford insights into the neurobiological
consequences of TBI, including those among persons with
mild TBI and postconcussive symptoms, which are not
amenable to detection using conventional structural
neuroimaging studies.
Conventional EEG may be abnormal in as many as 10%
of persons with mild TBI (Arciniegas et al 2004). Findings
on conventional EEG in this population most often include
mild disorganization of the background rhythms and/or a
mild excess of slow wave frequencies. Topographic brain
electrical activity mapping (BEAM) and quantitative EEG
(or QEEG) may demonstrate frontal and frontotemporal
abnormalities not evident on conventional EEG (Thatcher
et al 1989, 1998a, 1998b). When present, these abnormalities
are similar in type and location, although of lesser severity,
to those seen following severe TBI (Thatcher et al 2001).
Evoked potential and/or event-related potential (EP and ERP,
respectively) studies of persons with mild TBI also
demonstrate abnormal brain function (Gaetz et al 2000;
Gaetz and Weinberg 2000). The most robust correlations
between specific EP/ERP findings and clinical post-
concussive symptoms emerge when the electrophysiologic
procedures index dysfunction within the neural systems
related to those serving the cognitive and behavioral
functions in which the person is experiencing impairment
(Pratap-Chand et al 1988; Arciniegas et al 1999, 2001;
Arciniegas, Olincy et al 2000; Arciniegas and Topkoff 2004).
For example, persons with persistent attention and memory
impairments following mild TBI have been shown to
demonstrate abnormalities in the hippocampally-mediated
P50 evoked response (Arciniegas et al 1999, 2001;
Arciniegas, Olincy, et al 2000; Arciniegas and Topkoff 2004)
and the frontocentral P300 response (Pratap-Chand et al
1988). These abnormalities are strongly associated with the
function cortical areas involved in the generation of attention
and memory. Electrophysiologic abnormalities of these
types among persons with post-traumatic attention and
memory impairments offers additional support to the
hypothesis that mild TBI does in some cases give rise
to neurophysiologically-based persistent cognitive
impairments.
The findings from neuropathological, neuro-
physiological, neuroimaging, and electrophysiologic studies
of persons with mild TBI suggest that the traditional view
of these injuries as neurobiologically trivial requires serious
reconsideration. These studies support an approach to the
evaluation of persons with mild TBI that emphasizes the
recognition, identification, and evaluation of the
neurobiologic underpinnings of his or her postconcussive
symptoms. It is, however, important to be clear that the
findings from the neuroimaging and electrophysiologic
measures discussed in this section are, in most cases, not
specific to mild TBI; instead, they are most accurately
understood as reflecting neurobiological changes produced
by any condition that adversely affects the brain structures
and functions that these measures index. Accordingly, it is
imperative that clinicians bear in mind the differential
diagnosis of such findings if any of these measures are
employed in the clinical evaluation of persons with suspected
mild TBI. In fact, we suggest that it is premature to advocate
routine use of advanced structural or functional neuro-
imaging studies and/or unconventional electrophysiologic
studies in the evaluation of persons with persistent
postconcussive symptoms. Nonetheless, clinicians should
be mindful of the literature reviewed here before dismissing
a patient’s symptoms as “psychological” when conventional
neuroimaging and electrophysiologic studies are
unrevealing.
The postconcussive syndrome
There are important conceptual differences between mild
TBI, postconcussive symptoms, and the postconcussive
syndrome about which clinicians should be aware. Strictly
applied, the term “mild TBI” refers only to the initial injury
severity and should not be interpreted unequivocally as
suggesting mild outcome severity. Although both the
postconcussive syndrome and postconcussive symptoms are
most often discussed in the context of mild TBI, these
terms and their clinical referents are not synonymous with
mild TBI: mild TBI describes a type of injury whereas
postconcussive symptoms or syndrome describe a setNeuropsychiatric Disease and Treatment 2005:1(4) 315
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of problems resulting from TBI, including mild TBI
(Arciniegas and Silver 2001).
Postconcussive symptoms may develop following a TBI
of any severity, and are generally grouped into three
categories: cognitive, physical, and emotional/behavioral.
The term “postconcussive syndrome” (or postconcussional
disorder in the nosology of the DSM-IV [APA 1994])
generally denotes the development of a constellation of
physical, cognitive, and emotional/behavioral post-
concussive symptoms.
However, it is not clear there is a postconcussive
syndrome per se. Syndromes generally refer to conditions
in which there is both consistent symptom linkage and also
coupling of symptom resolution. Symptom linkage suggests
that the presence of symptom A predicts the presence of
symptoms B, C, and so on. Coupling of symptom resolution,
whether over time or in response to treatment, suggests that
the resolution of symptom A predicts resolution of symptom
B, C, and so on.
The studies of symptom occurrence and resolution
following mild TBI noted above do not offer strong support
for linkage between the types of symptoms experienced by
these persons. In other words, postconcussive symptoms
do not appear to cluster together in an invariate, or even in
a consistently predictable, fashion. The presence of somatic
symptoms is not linked predictably to the presence of
neuropsychiatric (ie, cognitive, emotional, or behavioral)
symptoms, and the neuropsychiatric sequelae of TBI are
not linked consistently to one another. This lack of symptom
linkage may reflect the complex effects of injury (focal,
diffuse, or both) on the brain and also the interaction between
each individual’s injury and his or her pre- or post-injury
psychosocial factors (Alexander 1995; King 1996) .
Additionally, there is little evidence of coupling of
symptom resolution following TBI. Few persons with
multiple postconcussive symptoms immediately after TBI
experience persistence of the entire set of their symptoms
over time, and instead maintain only a few, if any, of them
into the late post-injury period. Which of these initial
symptoms are maintained is also not reliably predictable
based on their early occurrence after TBI. Furthermore,
neither common clinical experience nor the medication
studies performed in this population to date (for a review,
see Arciniegas, Topkoff, et al 2000) support the concept of
a coupled response of postconcussive symptoms to
treatment. Instead, multiple and varied treatments are
generally required for the multiple and varied symptoms of
these individuals.
Both the lack of linkage between postconcussive
symptoms and the lack of coupling of symptom resolution
(spontaneously or in response to treatment) argues against
the concept of a postconcussive syndrome in the
conventional sense of the term “syndrome”. Accordingly,
the problems experienced by persons with mild TBI are more
accurately understood as “postconcussive symptoms” rather
than as a “postconcussive syndrome” per se. Using this
conceptual framework to understand the sequelae of mild
TBI facilitates consideration of each person’s postconcussive
symptoms as reflecting dysfunction of the brain areas to
which such symptoms are referable. Concurrently,
consideration of associated psychological or social
(including medicolegal) stressors is required to understand
the development and persistence of those symptoms,
particularly when those symptoms fail to conform to our
current understanding of brain-behavior relationships.
Evaluation and treatment of mild
TBI
Evaluation
The complexity and multiplicity of postconcussive
symptoms, the subtlety of the neurobiological consequences
of TBI, and the inescapability of psychosocial influences
on outcome following TBI necessitate an approach to the
treatment of persons with mild brain injury that begins with
a thorough neuropsychiatric evaluation. Care should be
taken to characterize clearly the initial injury using the
criteria offered by the ACRM described in the preceding
sections of this review: establishing whether an event that
is characterized fairly as a mild TBI indeed occurred is the
first and most critical step in the evaluation of persons with
possible postconcussive symptoms. It is sometimes difficult
to obtain reliable information regarding the occurrence and
duration of loss of consciousness, PTA, alteration of mental
status, and focal neurologic deficits from the individual with
a possible TBI. Individuals will often misinterpret a period
of PTA as a loss of consciousness: if events cannot be
remembered, the erroneous assumption that one was
unconsciousness during those events may be made.
Similarly, the very nature of an alteration in consciousness
may preclude accurate self-observation during that period,
thereby rendering any history obtained from the individual
him- or herself regarding the immediate injury period as
difficult-to-interpret at best. Accordingly, the ACRM criteria
should be used to probe for the possible occurrence of an
injury that produced alterations in cerebral functionNeuropsychiatric Disease and Treatment 2005:1(4) 316
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sufficient to meet the threshold of mild TBI; positive
responses should prompt efforts to obtain collateral
information from medical records and other reliable
information sources regarding the initial injury, particularly
if the clinician will be required to participate in the
medicolegal matters in which persons with TBI are
sometimes involved.
It is particularly important to define clearly the patient’s
postconcussive symptoms, as well as the course and
resolution (or lack thereof) of those symptoms since the
time of injury. As noted in the preceding section of this
article, postconcussive symptoms often do not conform in
either presentation or resolution to the traditional concept
of a syndrome. Nonetheless, many clinicians will attempt
to make a diagnosis of a postconcussive syndrome using
either the DSM-IV or ICD-10 definitions of this condition.
Unfortunately, these are not equivalent definitions (Boake
et al 2004), with the ICD-10 criteria for this condition being
more liberal than those of the DSM-IV by virtue of the
ICD-10’s lack of a criterion defining the clinical significance
of the postconcussive symptoms. It is also worth noting that
the DSM-IV states explicitly that its proposed criteria for
“postconcussional disorder” are not intended for application
to clinical practice but are instead intended to serve only as
a proposed set of criteria for further study. Accordingly, it
is our position that clinicians will serve better the persons
with TBI for whom they provide care by emphasizing a
thorough evaluation of specific postconcussive symptoms
rather than by attempting to establish whether or not those
symptoms and related disability conform to either the
DSM-IV or ICD-10 definitions of postconcussional disorder
or postconcussive syndrome, respectively.
The clinical presentation is expected to include at least
some elements of the classic constellation of postconcussive
symptoms and gradual, although sometimes incomplete,
symptomatic improvement over time. In the immediate post-
injury period, 80%–100% of persons with mild brain injury
will describe one or more symptoms reasonably attributable
to their injury, most commonly including headache, slowed
thinking, and/or impaired attention and memory (Levin,
Mattis, et al 1987; Stuss 1995; Dikmen et al 2001; McMillan
and Herbert 2004). About 50% of persons with mild TBI
demonstrate gradual, although sometimes incomplete,
recovery by three months post-injury (Dikmen et al 1986).
About 40% of persons with mild TBI experience the
persistence of postconcussive symptoms three to six months
post-injury (Ingebrigtsen et al 1998; McCullagh et al 2001),
and 1%–20% continue to experience one or more
postconcussive symptoms thereafter (Leininger et al 1990;
Levin and Eisenberg 1991; Beetar et al 1996; Deb et al
1999). Physical or cognitive symptoms with initial onset
weeks or months after TBI, symptoms that progressively
worsen over the months or years after injury, or symptoms
that are grossly out of proportion to the injury history and
objective (ie, neuropsychological, neuroimaging, or
electrophysiologic) testing may require explanations other
than TBI. Such histories should prompt consideration of
other potential contributors to the patient’s presentation,
including other neurological conditions, psychiatric
disturbances (ie, depression, anxiety, post-traumatic stress
disorder, pain, sleep disturbance), adverse medication
effects, psychosocial or medicolegal stressors, or some
combination of these.
Clarifying pre-injury developmental, medical,
neurological, psychiatric, substance, academic, and
employment histories is essential, particularly as regards
conditions that may influence recovery following mild TBI.
Prior TBI may be present in as many as 30% of these
individuals (Rimel et al 1981) and the presence of such may
also offer explanation for relatively poor recovery following
an apparently mild TBI. Substance abuse and/or intoxication
at the time of injury is important to note, as the association
of substance abuse with brain injury and relatively poor
psychological and functional outcome after TBI is well
described (Bigler et al 1996; Kolakowsky-Hayner et al 1999;
Bombardier et al 2002; MacMillan et al 2002; Ashman et al
2004). Depression, anxiety disorders, post-traumatic stress
disorder, and sleep disturbances may develop after TBI, and
premorbid disorders of these types may be exacerbated by
mild TBI. In the context of TBI, these disorders may present
atypically with respect to conventional symptom clusters
and diagnostic boundaries. Consequently, clinicians should
be flexible with respect to the diagnosis and treatment of
these conditions in the brain-injured patient. Conversely,
psychiatric and substance disorders, cranial and cervical
trauma, and other primary neurological and somatic
disorders may produce symptoms that overlap with those
commonly produced by TBI. As noted earlier, interpreting
these symptoms accurately requires that clinicians ascertain
the occurrence of a definable TBI and assess their
relationship to and consistency with the natural course of
symptom development and resolution following TBI.
A thorough physical and neuropsychiatric examination
is an essential part of the evaluation of the brain-injured
individual. The physical examination should include a
detailed neurological examination, including assessment forNeuropsychiatric Disease and Treatment 2005:1(4) 317
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primitive reflexes (“frontal release signs”) and other
neurological “soft-signs” that may reflect subtle
neurological dysfunction not evidenced by routine
(“elemental”) neurological examination. Neuropsychiatric
assessment should include a thorough general mental status
examination as well as a detailed cognitive examination;
the latter examination should emphasize timed tests of
attention and information processing, memory encoding and
retrieval, and executive function. Clinicians should be aware
that the Mini-Mental State Examination (MMSE) (Folstein
et al 1975) is not generally regarded by brain injury
specialists as an adequate tool with which to screen for the
types of cognitive impairment produced by mild TBI. The
anatomy of TBI, whether of mild or greater severity, predicts
greater impairments in frontally-mediated cognitive
functions rather than in the medial temporal and
bitemporoparietal cognitive functions assessed by the
MMSE (Brooks et al 1999). Accordingly, bedside measures
with greater sensitivity to deficits in frontally-mediated
cognition such as the Frontal Assessment Battery (Dubois
et al 2000) or the Behavioral Dyscontrol Scale (Kaye et al
1990; Grigsby et al 1992) may improve detection of
functionally-relevant cognitive impairments among persons
with mild TBI (Leahy et al 2003; Suchy et al 2003).
Clinicians unfamiliar with the administration and
interpretation of bedside measures that assess frontally-
mediated cognition should consider referring the person with
brain injury and cognitive symptoms for formal neuro-
psychological testing. Quantification of postconcussive
symptoms using standardized scales developed for this
purpose (Levin, High, et al 1987; Crawford et al 1996;
Kreutzer et al 1999) also may guide usefully the diagnosis
and treatment of persons with postconcussive symptoms.
Neuroimaging and electrophysiological assessments
may also provide corroborative evidence of injury type and
severity. The results of such neuroimaging and neuro-
diagnostic studies must be interpreted in light of their
sensitivity to the effects of mild TBI and with respect to the
timing of their acquisition in relation to the injury. These
studies are rarely diagnostic, but may provide useful
evidence in support of a history of traumatic brain injury,
and may offer explanation for the specific types of
postconcussive symptoms experienced by a person with mild
TBI (Smith et al 1995; Hofman et al 2001; Davalos and
Bennett 2002; Hillary et al 2002). However, advanced
neuroimaging and neurodiagnostic studies are not
recommended for routine use in the evaluation of persons
with mild TBI. Instead, their use should be reserved for the
evaluation of persons with TBI in whom standard clinical
evaluations have not yielded adequate explanation for
presenting symptoms. Whether conventional or advanced
neuroimaging and neurodiagnostic methods are employed,
clinicians should remain mindful that the absence of
evidence of TBI on conventional neuroimaging does not
constitute evidence of an absence of TBI. If the history and
clinical presentation support a diagnosis of mild TBI and
the onset and pattern of postconcussive symptoms is, in the
judgment of the evaluating physician, consistent with that
diagnosis then the lack of neuroimaging and/or
electrophysiologic abnormalities may be understood as
reflecting the relative insensitivity of such studies to the
types of abnormalities produced by mild TBI.
Clinicians are encouraged to undertake a thorough
neuropsychiatric evaluation of the sort described above
before establishing a diagnosis of mild TBI, and are
particularly encouraged to do so before excluding such a
diagnosis from consideration. It is important to reiterate that
while somatization and malingering do occur among persons
with mild TBI (Slick et al 1994; Paniak et al 2002;
Langeluddecke and Lucas 2003), these are relatively
uncommon, if not frankly rare, conditions even in the context
of medicolegal proceedings (Iverson and Binder 2000). The
initiation of compensation claims should not be
misunderstood as arising solely from the pursuit of primary
or secondary gains (eg, money, role change, or other external
incentives). Such claims more often reflect the occurrence
and persistence of postconcussive symptoms and related
disabilities arising as a result of TBI, although they may be
complicated by injury-related exacerbation of pre-injury
psychological or neuropsychiatric problems, the pursuit of
primary or secondary gains, or a complex interaction
between these factors (Binder 1986; Feinstein et al 2001).
Without question, malingering and somatization should not
be the first or the default diagnoses when individuals
present with difficult-to-diagnose symptoms following TBI
and/or are involved in litigation related to their injuries.
Attribution of symptoms to malingering should be avoided
unless: (1) the patient demonstrates incontrovertible
evidence of such on multiple neuropsychological measures
designed for the specific identification of this problem (ie,
demonstrates a pattern of response bias that can only be
explained as an attempt to “fake bad” on cognitive testing);
and (2) there is clear demonstration of function in everyday
life that is inconsistent with reported symptoms and/or
disabilities and that cannot be accounted for by other
neuropsychiatric factors.Neuropsychiatric Disease and Treatment 2005:1(4) 318
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Treatment
Treatment should be predicated upon the type of thorough
neuropsychiatric evaluation described in the preceding
section. The presence of comorbid psychiatric problems
such as a major depressive episode, anxiety disorders
(including post-traumatic stress disorder), or substance
abuse – whether or not these are regarded as etiologically
related to the mild TBI – should be treated aggressively using
appropriate psychotherapeutic and pharmacologic
interventions. It is important to be aware that even when
psychiatric, neurological (eg, seizure), or other bodily injury
issues (eg, pain) are present, one cannot assume that all of
the individual’s postconcussive symptoms are fully or best
accounted for by these conditions. Therefore, assessment
for residual (or uncoupled) postconcussive symptoms should
be ongoing during treatment of post-traumatic psychiatric,
neurological, and physical conditions. The persistence of
some postconcussive symptoms despite the effective
treatment for others does not necessarily suggest treatment
failure, but may instead indicate the need for additional
therapies targeting specific residual postconcussive
symptoms.
Education early after a mild TBI includes the symptoms
it produces, the usual time course for resolution of these
symptoms, and the potential for long-term difficulties, which
may decrease the likelihood of developing persistent
postconcussive symptoms (Paniak et al 1998; Wade et al
2001). These interventions are most effective when offered
not only to the person with mild TBI but also to that person’s
family, friends, employers, insurers, and/or significant
others. Education of this sort is particularly important in
the context of mild TBI: the often apparently “mild”
mechanism of injury and the affected person’s otherwise
healthy appearance may lead some patients and families to
minimize or disregard entirely the relationship between the
injury, subsequent symptoms, and functional impairments.
The clinician should offer validation of the person’s
experience of symptoms, regardless of their cause, without
fostering illness behaviors. This validation is best coupled
with the development of individualized and realistic goals
for return to major activities and employment. The
development of such goals should involve key stakeholders
in the brain-injured person’s life (eg, patient, significant
others, employers, payors), and recovery goals should not
be offered in a proscriptive, “one size fits all” manner.
Nonpharmacologic rehabilitative therapies are useful in
the treatment of cognitive and physical symptoms following
mild TBI. Although cognitive rehabilitation is a subject of
some controversy, the American Congress of Rehabilitation
Medicine promulgated guidelines and recommendations for
cognitive rehabilitation strategies based on a review of the
treatment literature in this area (Cicerone et al 2000). While
there are relatively few randomized controlled trials of these
treatments in the TBI population, there is evidence
suggesting that when properly applied they may be of benefit
for the treatment of memory, attention, executive function,
and communication deficits among reasonably high-
functioning and well motivated persons with TBI.
At present, no medication has received approval from
the United States Food and Drug Administration (FDA) for
the treatment of any neuropsychiatric consequence of TBI.
The lack of FDA approved treatments in this population is,
in the opinion of the authors, a reflection of medicoeconomic
issues rather than of the science relevant to the development
of such treatments. However, given the absence of FDA
approved pharmacotherapies for neuropsychiatric problems
after TBI, clinicians should be mindful that all treatments
for the neuropsychiatric sequelae of TBI must be regarded
as “off-label”. Where possible, clinicians should predicate
the treatments they offer on the published literature specific
to the neuropsychiatry of TBI. Unfortunately, randomized,
double-blind, placebo-controlled, trials are uncommon in
this literature and the vast majority of the treatment literature
for the neuropsychiatric sequelae of TBI consists of open-
label case series or single case reports (Arciniegas, Topkoff,
et al 2000). In the absence of published studies with which
to guide treatment, the selection of pharmacologic agents is
generally modeled after the approach used to select such
agents for patients with cognitive, emotional, or somatic
symptoms arising from other neurological or primary
psychiatric conditions.
When pharmacologic therapies are used, the indications
and need for ongoing prescriptions should be reviewed, and
efforts should be made to eliminate those not affording clear
benefits or that are potentially worsening postconcussive
symptoms. Excepting agents for which there are peer-
reviewed publications describing safety, tolerability, and
effectiveness for postconcussive symptoms, the use of over-
the-counter (OTC), herbal, and other supplemental agents
in this population should be discouraged. Many of these
may adversely affect cognition (particularly OTC “sleeping
pills” containing scopolamine) and may negatively interact
with prescribed medications (Wong et al 1998; Spinella and
Eaton 2002).
Specific target symptoms should be identified before and
reassessed assiduously during treatment, and the use ofNeuropsychiatric Disease and Treatment 2005:1(4) 319
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standardized assessment tools for this purpose is
encouraged. A “start low, go slow” approach is prudent, as
persons with TBI are particularly susceptible to adverse
effects from both a variety of commonly used psychotropic
medications and from rapid dose escalation. Nonetheless,
it is important to note that some persons with neuro-
psychiatric problems following TBI will require standard
therapeutic doses to achieve substantial relief from those
problems. Finally, particular attention should be given to
side effects and possible drug–drug interactions when
prescribing any combination of medications in this
population.
Treatment of postconcussive cognitive
impairments
Catecholaminergic and cholinergic dysfunction may be
involved in the genesis of attention, memory, and executive
function impairments after TBI. Consequently, most of the
treatments for these problems are used for the purpose of
augmenting the function of these neurotransmitter systems.
In the acute rehabilitation setting, methylphenidate may
improve attention and hasten the rate of functional recovery
during the post-acute recovery period after TBI (Kaelin et
al 1996; Plenger et al 1996). Arousal and speed of
information processing may be also improved by
methylphenidate, even where no significant effects are
observed on other aspects of attention or motor performance
(Whyte et al 1997). Methylphenidate may also reduce mood
disturbances occurring in the context of post-TBI cognitive
impairments (Gualtieri and Evans 1988), and has been
reported to improve post-TBI aggression even in the absence
of observable effects on cognition (Speech et al 1993). The
duration of benefit from methylphenidate treatment in this
population is not clear, but common clinical experience
suggests that appropriately treated individuals may sustain
one or several of these benefits during years of treatment,
and typically do so without the development of tachy-
phylaxis or dependence to methylphenidate. Importantly,
methylphenidate does not appear to reduce seizure threshold
in persons with TBI, including those with active seizure
disorders (Wroblewski et al 1992). Accordingly, while the
possible occurrence of seizures during treatment with
methylphenidate should be included in the process of
providing informed consent, it should be communicated as
an unlikely possibility.
Case reports and case series suggest that dextro-
amphetamine (Evans et al 1987), amantadine (Gualtieri et
al 1989; Nickels et al 1994; Kraus and Maki 1997),
bromocriptine (McDowell et al 1998), and L-dopa/carbidopa
(Lal et al 1988) also may improve arousal, some aspects of
attention, and executive function among persons with post-
traumatic impairments in these cognitive domains. The latter
three of these medications may also reduce the severity of
diminished motivation (apathy) following TBI (Lal et al
1988; Van Reekum et al 1995; McDowell et al 1998), and
amantadine may also reduce agitation, aggression, and
affective lability (Van Reekum et al 1995).
Cholinesterase inhibitors may improve attention and
memory deficits produced by TBI, both in the acute
(Bogdanovitch et al 1975; Levin et al 1986) and late post-
injury periods (Goldberg et al 1982; Cardenas et al 1994;
Eames and Sutton 1995). Among the modern cholinesterase
inhibitors, donepezil is the only agent for which there are
specific reports of use in the TBI population. Several reports
(Taverni et al 1998; Whelan et al 2000; Masanic et al 2001;
Kaye et al 2003; Morey et al 2003; Walker et al 2004; Zhang
et al 2004) suggest that this medication may be of benefit
for the treatment of attention and/or memory impairments
in both the acute and late periods following TBI, including
mild TBI. Whether or not the other presently-available
cholinesterase inhibitors (ie, rivastigmine, galantamine)
afford similar benefits is not clear, but anecdotal reports
suggest that the benefits attendant to these medications is
mostly likely a class effect rather than a medication-specific
one.
Cytidine 5´-diphosphocholine (CDP-choline or
citicoline) is an essential intermediate in the biosynthetic
pathway of phospholipids incorporated into cell membranes,
and its orally ingested form appears to activate the
biosynthesis of structural phospholipids in neuronal
membranes, increase cerebral metabolism, and enhance the
activity of dopamine, norepinephrine, and acetylcholine in
the brain (Secades and Frontera 1995; Dixon et al 1997). In
light of these properties, CDP-choline has been studied as a
treatment for post-traumatic cognitive impairments.
Calatayud et al (1991), in a single-blind randomized study
of 216 patients with severe or moderate TBI during the acute
post-injury period, observed improvements in motor,
cognitive, and psychiatric function during treatment with
CDP-choline, and use of the agent was associated with
decreased length of stay in the hospital. Levin (1991), in a
double blind, placebo-controlled study of 14 patients to
evaluate the efficacy of CDP-choline for treating
postconcussional symptoms in the first month after mild to
moderate TBI, reported reduced severity of postconcussionalNeuropsychiatric Disease and Treatment 2005:1(4) 320
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symptoms and improved recognition memory for designs
during treatment with this agent. Although these findings
are encouraging of CDP-choline’s abilities to facilitate
recovery during the acute post-injury period in persons with
TBI, the lack of rigorous FDA scrutiny of the safety,
tolerability, and efficacy of this agent preclude
recommending routine use of CDP-choline in this
population. However, for patients unwilling or unable to
take other prescribed medications, CDP-choline may be a
“nutritional supplement” that some patients may find
acceptable and of modest benefit.
In clinical practice, some patients respond to
psychostimulants, some to cholinesterase inhibitors, some
to both, and others to neither class of medication. At present,
there are no widely available methods of identifying
dopaminergic or cholinergic function for the purpose of
predicting treatment response. Hence, treatment selection
is best made on the basis of the patient’s predominant
symptoms and/or comorbid neuropsychiatric symptoms or
conditions. Stimulants appear to be the first choice for the
pharmacologic treatment of impaired attention with or
without comorbid hypoarousal, apathy, fatigue, or depressed
mood. The cholinesterase inhibitors may be a better first
choice when memory impairments are the predominant
clinical problem or when there is concern that use of a
stimulant may exacerbate other postconcussive symptoms
(eg, sleep disturbance). There is no consensus regarding the
treatment of cognitive impairments among persons with TBI
and substance use disorders, but most clinicians avoid the
traditional psychostimulants (ie, methylphenidate,
dextroamphetamine) and instead favor the use of agents with
a lower potential for abuse or dependency (ie, amantadine,
cholinesterase inhibitors). As noted above, CDP-choline
may be an alternative treatment strategy when there is
concern regarding the potential for complicating other
neuropsychiatric symptoms or conditions. However, the lack
of regulated production of this medication requires that
additional vigilance for both beneficial and adverse effects
be maintained when its use is undertaken.
Treatment of postconcussive emotional
disturbances
The treatment of emotional disturbances (eg, depression,
anxiety, affective lability, irritability) is similar to the
treatment of phenotypically similar problems in the non-
injured populations. There are no published randomized,
double-blind, placebo-controlled trials of any treatment for
depression following TBI. However, the available literature
suggests that the selective serotonin reuptake inhibitors
(SSRIs) are likely to be both more effective and better
tolerated as first-line treatments for depression and/or
affective lability in this population. Although all of the
SSRIs may be of use for the treatment of depression, anxiety,
and/or irritability following TBI, the authors recommend
using agents lacking potent antimuscarinic effects and
having relatively short half-lives (ie, sertraline, citalopram,
escitalopram).
Depression is a common consequence of TBI, with a
frequency of 10%–60% in the first year post-injury (Hibbard
et al 1998; Dikmen et al 2004; O’Donnell et al 2004) and
up to 17% even 3–5 years post-injury (Dikmen et al 2004).
Among the published reports describing the use of sertraline,
the study of Fann et al (2000) offers the clearest description
of treatment-induced improvements in depressive symptoms
following mild TBI. In that study, which was a single-blind
trial among persons with major depression 3–24 months
after a mild traumatic brain injury, sertraline 25–200 mg
resulted in marked reductions in depressive symptoms, self-
reported postconcussive symptoms, and self-reported
symptomatic distress. In a subsequent report, Fann et al
(2001) describe sertraline’s additional benefits on cognitive
performance and perception of cognitive and other
postconcussive symptoms among persons whose depressive
symptoms responded to this treatment.
Tricyclic antidepressants may be of benefit for
postconcussive depressive symptoms, but may not be as
effective in this population as in comparably ill individuals
with primary depressive disorders (Saran 1985; Varney et
al 1987; Dinan and Mobayed 1992; Wroblewski et al 1996).
Additionally, tricyclic antidepressants appear to be
associated with an increased risk of adverse effects such as
seizures when used in the acute post-injury period
(Wroblewski et al 1990). Of note, there are at the time of
this writing no reports offering support for the use of newer
antidepressants such as venlafaxine, buproprion,
mirtazapine, or nefazodone in the treatment of depression
after TBI. Although anecdotal reports suggest that these
agents may be of benefit for the treatment of postconcussive
emotional symptoms, their use should be undertaken with
caution given the absence of information regarding the
safety, tolerability, and effectiveness in this population.
Affective lability is also common among persons with
TBI, with a prevalence of approximately 11% in the first
year post-injury (Tateno et al 2004). Breen and Goldman
(1997) and Muller et al (1999) report reductions in affective
lability produced by brain injury during treatment withNeuropsychiatric Disease and Treatment 2005:1(4) 321
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paroxetine. Muller et al (1999) also compared the
effectiveness of paroxetine with citalopram for the treatment
of affective lability after brain injury (stroke or TBI); while
both medications were comparably effective, citalopram was
better tolerated. Whether or not the relatively more
prominent adverse effects of paroxetine are a function of
its antimuscarinic effects is unclear, but this differential in
adverse effects merits some consideration when considering
the use of paroxetine in this population. As is often seen in
the treatment of affective lability in other neurological
conditions, the response of affective lability due to TBI is
often more rapid (ie, days rather than weeks) than that
typically observed for post-traumatic depression. When
affective lability is a target of pharmacotherapy, the authors
recommend as first-line treatments SSRIs with relatively
short half-lives and lacking potent antimuscarinic properties.
Although irritability, paroxysmal aggression, and mania
may develop after a mild TBI (Hibbard et al 1998), these
problems are relatively uncommon consequences of such
injuries, and the optimal treatments for these problems are
not clear at present. The limited published case literature
and expert opinions suggest that anticonvulsant mood
stabilizers are preferable to lithium carbonate for the
treatment of these problems (Arciniegas, Topkoff, et al
2000), although lithium carbonate may be of benefit in some
persons with such symptoms following TBI (Zwil et al
1993). In general, when severe irritability, paroxysmal
aggression, and mania are the predominant features of the
clinical presentation in a person with TBI we recommend
consultation with a neuropsychiatrist, behavioral
neurologist, or neurorehabilitation specialist with expertise
in the management of these postconcussive symptoms.
Treatment of postconcussive somatic
symptoms
Typical postconcussive somatic symptoms include head-
ache, dizziness, pain, seizures, fatigue, visual disturbance,
hyposmia, and hyperacusis. A detailed discussion of the
evaluation and treatments for postconcussive somatic
symptoms is beyond the scope of this review, but a brief
discussion of the treatment of the most common
postconcussive somatic symptoms in the context of the
neuropsychiatric care of persons with TBI are offered here.
Maintaining effective communication between
healthcare providers involved in the provision of treatments
for such symptoms is essential for the delivery of a
coordinated and effective treatment program. When
pharmacotherapies are used, clinicians should be mindful
of the lack of clinical data to guide the treatment of
postconcussive somatic symptoms. To date, there are no
controlled clinical trials for the treatment of headache, sleep
disturbance, or fatigue in this population despite the high
frequency of these symptoms following TBI. Consequently,
the selection of pharmacotherapies for postconcussive
somatic symptoms is generally guided by those selected for
persons with phenotypically similar but etiologically distinct
conditions. Nonpharmacologic therapies should be used
where such are feasible and appropriate.
Post-traumatic headache is the most common, and may
be the most persistent, post-traumatic somatic symptom
(Goldstein 1991; Bell et al 1999; Martelli et al 1999; Ryan
and Warden 2003). Although there is considerable debate
regarding the classification and treatment of postconcussive
headaches (Packard 1999; Zasler 1999), this problem often
requires evaluation and treatment in both the acute and late
post-injury periods. When present, post-traumatic headache
presents a serious confound to the assessment of other
postconcussive symptoms, and particularly post-traumatic
cognitive impairments (Martelli et al 1999; Nicholson et al
2001). The differential diagnosis of post-traumatic
headaches is broad, and includes myofascial pain, cervico-
zygapophyseal joint pain, neuritic pain, and craniocervical
somatic pain, among other such conditions (Bell et al 1999;
Packard 1999). As with most other types of headache,
combinations of medication and nonpharmacological
interventions are generally required. The phenomenology
of post-traumatic headache appears to conform to the
diagnostic criteria of the International Headache Society
(Packard and Ham 1994, 1997; Packard 2005). Con-
sequently, treatment of post-traumatic migraine or tension
headaches generally uses the same set of abortive and
prophylactic agents used in the treatment of their idiopathic
counterparts. Given the frequency and complexity of post-
traumatic headaches and their potential interactive and
complicating effects on other postconcussive symptoms,
collaboration with a multidisciplinary rehabilitation team
including a physiatrist or neurologist with expertise in the
evaluation and treatment of postconcussive headaches is
strongly encouraged.
Similarly, postconcussive dizziness (Chamelian and
Feinstein 2004; Marzo et al 2004), sleep disturbance (Rao
and Rollings 2002), and fatigue (Parsons and Ver Beek 1982;
Perlis et al 1997), are common, and their occurrence may
confound the neuropsychiatric assessment of persons with
mild TBI. The use of anticholinergic agents for post-
traumatic dizziness is common in clinical practice, but mustNeuropsychiatric Disease and Treatment 2005:1(4) 322
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be undertaken with vigilance for treatment-emergent
cognitive impairment in light of the role of cholinergic
deficits in post-traumatic cognitive impairments (Arciniegas
2003). Nonpharmacologic interventions for post-traumatic
dizziness may be useful as an alternative to pharmaco-
therapies (de Kruijk et al 2002), although the effectiveness
of such interventions is not fully established.
Treatment of sleep disturbance following TBI is
commonly undertaken with trazodone as the first-line
pharmacotherapy (Rao and Rollings 2002). Most experts
suggest avoiding benzodiazepines for post-traumatic sleep
disturbances, where possible, in light of their propensity
for reducing arousal, impairing cognition, and exacerbating
motor impairments (Bleiberg et al 1993; Buffett-Jerrott and
Stewart 2002), and also in light of the small but nontrivial
risk of paradoxical agitation associated with their use in
neurologically impaired patients (Fouilladieu et al 1985).
Behavioral interventions directed at improving sleep hygiene
as well as the development of relaxation techniques may
also be of use in the treatment of post-traumatic sleep
disturbances (Rao and Rollings 2002).
Fatigue may occur independently of other post-traumatic
neuropsychiatric disturbances. When treatment of other
post-traumatic neuropsychiatric and/or somatic problems
does not adequately improve fatigue, specific treatment of
this problem may be required. Psychostimulants and
amantadine are the most commonly used agents for the
treatment of fatigue in persons with TBI, and may be of
some benefit toward that end. In our experience, the dose
of agents similar to that employed for the treatment of
diminished arousal and attention is usually sufficient to treat
post-traumatic fatigue. These medications may be of
particular benefit in patients with post-traumatic depression
in whom fatigue persists despite improvement in mood
during treatment with antidepressants.
Modafinil, a medication recently approved for the
treatment of excessive daytime somnolence in patients with
narcolepsy, also may have a role in treatment of post-TBI
fatigue (Elovic 2000). Teitelman (2001) described the use
of modafinil among 10 outpatients with nonpenetrating
traumatic brain injury and functionally significant excessive
daytime sleepiness, and in two patients with somnolence
due to sedating psychiatric medications. Doses of modafinil
ranged between 100 mg and 400 mg taken once each
morning, to which nine of these patients reported
improvements in excessive daytime sleepiness. In this open-
label case series, Teitelman (2001) also notes that some
patients also reported subjective improvements in attention
as well as other cognitive benefits. Although this medication
was generally well tolerated, two patients developed
increased “emotional instability”. Although it is premature
to advocate the routine use of modafinil for the treatment of
post-traumatic fatigue, this agent may be in some cases be
useful for this purpose.
For some persons with TBI, selecting agents whose
effects may afford the reduction of several target symptoms
may be useful. For example, sleep disturbance, post-
traumatic headaches, and chronic cervical (neck) pain might
benefit from an anticonvulsant at night, the effects of which
may confer some relief from each of these problems,
particularly when the patient is also experiencing post-
traumatic irritability or aggression. Alternatively, an
individual with post-traumatic depression, affective lability,
and headache might benefit from treatment with either an
SSRI or low-doses of a serotonergically-potent tricyclic
antidepressant with relatively limited anticholinergic effects
(ie, nortriptyline or desipramine).
To the extent that targeting multiple symptoms with
agents affecting multiple symptom domains is feasible and
effective, the potentially adverse consequences of
polypharmacy in this population may be limited. However,
clinicians should bear in mind the issue raised earlier in
this paper with respect to uncoupling of postconcussive
symptom response to treatment and remain open to carefully
employing multiple medications during treatment of
postconcussive symptoms. When post-traumatic somatic
symptoms such as those described above require treatment,
the involvement of a multidisciplinary team, and particularly
physiatrists and/or neurologists with expertise in the
evaluation and treatment of these problems, is often
necessary and may be highly productive.
Conclusion
Cognitive, emotional, behavioral, and physical impairments
are common sequelae of mild TBI and may in a nontrivial
minority of persons persist into the late period following
injury. Typical postconcussive symptoms include headache,
dizziness, and visual disturbances; attention, memory, and
other cognitive impairments; irritability, anxiety, depression,
and other emotional disturbances; and behavioral problems
such as apathy or impulsivity. The evaluation of
postconcussive symptoms requires an understanding of the
multiple factors relevant to the production and maintenance
of symptoms following trauma to the brain. Despite theNeuropsychiatric Disease and Treatment 2005:1(4) 323
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skepticism particularly common to discussion of post-
concussive symptoms in medicolegal contexts, recent studies
suggest that the neurobiological effects of TBI are not trivial
and may produce dysfunction in one or more areas of the
central nervous system. The characterization of these
symptoms as a postconcussive syndrome is dubious, and in
the opinion of the authors it is more accurate to describe
these symptoms as frequently co-occurring postconcussive
symptoms rather than as a postconcussive syndrome.
Treatment of postconcussive symptoms necessitates a
thorough and accurate assessment of the factors involved
in the genesis and maintenance of the symptoms. Education,
nonpharmacologic interventions, and some symptom-
targeted pharmacotherapies, as well as encouraging patience
during the time required for spontaneous recovery after mild
TBI may afford substantial reductions in postconcussive
symptoms and improvements in everyday function. An
individualized, flexible, and multi-faceted treatment plan
involving the principles described herein – best described
as a neurobiopsychosocial approach – appears to offer the
patient with postconcussive symptoms following mild TBI
the best hope for symptomatic and functional recovery.
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